HONG KONG, Dec. 17 /PRNewswire-Asia/ -- China's leading high-tech healthcare group, Golden Meditech Company Limited ("Golden Meditech" or "the Group"; Stock Code: 801) is pleased to announce today that the Group's associate company FunTalk China Holdings Limited (FunTalk), formerly known as Pypo China Holdings Limited, made its debut on the NASDAQ exchange (Nasdaq: FTLK) after a successful secondary offering. The shares of FunTalk started trading on December 17, 2009 morning (Eastern Time).
As of today, Golden Meditech holds 15 million FunTalk shares. Based on the offering price of US$7 per share, the Group's holding is valued at US$105 million.
FunTalk is one of the largest nationwide distributors and retailers of personal wireless communications devices in China, dedicated to nationwide sales and distribution of advanced and fashionable mobile handsets, accessories and value-adding content. The Company runs a national network of branch offices and distribution centers servicing approximately 10,000 retail outlets in over 350 cities nationwide. FunTalk China is considered the largest mobile phone retail chain in China in terms of annual sales volume and total floor space of its retail outlets integrated under the brand name of "FUNTALK."
Investors responded positively to this offering. FunTalk issued 3.1 million ordinary shares and raised US$21.7 million dollars. Renowned investment bank Roadman & Renshaw is the sponsor and lead underwriter for this offering.
Mr. KAM Yuen, Chairman and CEO of Golden Meditech, said, "The listing of FunTalk China on NASDAQ represents another successful investment that the Golden Meditech management team has made in China, with its valuation tripled in less than three years. This is also the third company that the Group has invested in and has gone public in the United States within the past four years."
About Golden Meditech:
Golden Meditech was listed on the Stock Exchange of Hong Kong Limited (HKEX) as the first hi-tech medical device enterprise that went public outside of the PRC. Thanks to its great efforts in innovation and market expansion, as well as its first-mover abilities in capturing the emerging market opportunities, Golden Meditech's medical devices, cord blood banking services and innovative natural herbal medicines have all established dominant positions in their own sectors over the past years. Going forward, Golden Meditech will continue its pursuit of becoming China's leading integrated medical group through organic growth, acquisitions and strategic investments.
For further information, please contact: Golden Meditech Company Limited Investor Relations Division Add: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong Tel: +852-3605-8138 Fax: +852-3605-8181 Email: firstname.lastname@example.org
SOURCE Golden Meditech Company Limited
|SOURCE Golden Meditech Company Limited|
Copyright©2009 PR Newswire.
All rights reserved